IAM Advisory LLC Has $1.48 Million Holdings in Novartis AG (NYSE:NVS)

IAM Advisory LLC raised its holdings in Novartis AG (NYSE:NVS) by 1.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 15,160 shares of the company’s stock after acquiring an additional 247 shares during the quarter. IAM Advisory LLC’s holdings in Novartis were worth $1,475,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Legacy Investment Solutions LLC acquired a new stake in shares of Novartis in the third quarter valued at about $28,000. Fortitude Family Office LLC increased its position in shares of Novartis by 503.8% during the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after purchasing an additional 267 shares during the last quarter. Clean Yield Group bought a new stake in shares of Novartis during the 3rd quarter worth approximately $43,000. Brooklyn Investment Group acquired a new stake in shares of Novartis in the 4th quarter valued at approximately $55,000. Finally, Beaird Harris Wealth Management LLC raised its position in Novartis by 280.5% during the third quarter. Beaird Harris Wealth Management LLC now owns 704 shares of the company’s stock worth $81,000 after acquiring an additional 519 shares in the last quarter. 13.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NVS has been the topic of several recent analyst reports. Erste Group Bank restated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets lifted their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $121.50.

Novartis Price Performance

Shares of NYSE:NVS opened at $97.51 on Friday. The firm has a 50 day moving average of $100.61 and a 200-day moving average of $108.99. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $199.30 billion, a PE ratio of 11.32, a PEG ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. The business had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period in the previous year, the business earned $1.74 earnings per share. On average, equities research analysts predict that Novartis AG will post 7.63 EPS for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.